Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Journal: The Journal of rheumatology
Published: January 04, 2019
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
Journal: Arthritis research & therapy
Published: December 17, 2018
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Journal: The Journal of rheumatology
Published: July 01, 2018
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
Journal: Annals of the rheumatic diseases
Published: February 19, 2018
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Journal: The Journal of clinical investigation
Published: November 21, 2017
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 02, 2017
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
Journal: Annals of the rheumatic diseases
Published: September 28, 2017
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
Journal: Clinical pharmacology and therapeutics
Published: September 25, 2017
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: September 12, 2017
Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 02, 2017
Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
Journal: Modern rheumatology
Published: April 26, 2017
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Journal: The New England journal of medicine
Published: February 16, 2017
Last Updated: 09/26/2026